UPDATE 1-Novartis digs deeper into cancer with up to $750 mln Aduro deal

* Novartis also picks top scientist to lead immuno-oncology (Adds details on Aduro's planned IPO, analyst comment)
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.